Drug Profile
Pegarginase - Bio-Cancer Treatment International
Alternative Names: BCT-100; PEG-arginase - Bio-Cancer Treatment International; PEG-BCT-100; PEGylated recombinant human arginase - Bio-Cancer Treatment International; Recombinant human arginase 1 - Bio-Cancer Treatment International; Recombinant human arginase I - Bio-Cancer Treatment International; rhArg1 - Bio-Cancer Treatment International; rhArgI - Bio-Cancer Treatment International; rhArgIpeg5000Latest Information Update: 30 Dec 2022
Price :
$50
*
At a glance
- Originator Bio-Cancer Treatment International
- Class Antineoplastics; Polyethylene glycols; Ureohydrolases
- Mechanism of Action Arginase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Acute myeloid leukaemia; Liver cancer
- Phase I/II Solid tumours
- Suspended Leukaemia; Lymphoma
Most Recent Events
- 30 Dec 2022 Pegarginase is still in phase I/II trial for Solid tumours (Second-line therapy or greater, In adolescents, In adults, In infants, In children) in Australia, Ireland, the Netherlands, United Kingdom (IV) (EudraCT2017-002762-44) (NCT03455140)
- 22 Jul 2022 University of Birmingham completes a phase I/II trial in Solid tumours (Second-line therapy or greater, In adolescents, In adults, In infants, In children) in Australia, Ireland, the Netherlands, United Kingdom (IV) (EudraCT2017-002762-44) (NCT03455140)
- 06 Mar 2018 University of Birmingham plans the phase I/II PARC trial for Solid tumours (Late-stage disease, Second-line therapy or greater) (IV, Infusion) (NCT03455140)